Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 17 years ago
 
		QualityStocks		
			Vyteris, Inc. (OTC BB: VYTR)
				Tags Rodman & Renshaw
		
			    	
				    Related Post
					
			- 
											                QualityStocksNewsBreaks – NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…
 - 
											                QualityStocksNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FRA: GDT0) Launches Corporate and Premium Cybersecurity Plans
This article has been disseminated on behalf of Sekur Private Data and may include paid…
 - 
											                Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the…